Ablative Solutions' TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation

/PRNewswire/ -- Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal...

Related Keywords

United States ,Kate Rumrill ,David Kandzari ,Ablative Solutions ,American College Of Cardiology ,Scientific Congress ,Piedmont Heart Institute ,Prnewswire Ablative Solutions Inc ,Ablative Solutions Inc ,Late Breaking Clinical Trial ,Primary Endpoint ,Uncontrolled Hypertension ,Treatment Arm ,Pivotal Trial ,Peregrine System ,American College ,Annual Scientific Congress ,Peregrine System Kit ,Piedmont Healthcare ,Breaking Clinical Trial ,Ambulatory Systolic Blood Pressure ,Major Adverse Events ,Peregrine System Infusion Catheter ,Nc ,Health Care Amp Hospitals ,Clinical Trials Amp Medical Discoveries ,